BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34584128)

  • 1. TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer.
    Kuno I; Takayanagi D; Asami Y; Murakami N; Matsuda M; Shimada Y; Hirose S; Kato MK; Komatsu M; Hamamoto R; Okuma K; Kohno T; Itami J; Yoshida H; Shiraishi K; Kato T
    Sci Rep; 2021 Sep; 11(1):19261. PubMed ID: 34584128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new marker based on risk stratification of human papillomavirus DNA and tumor size to predict survival of locally advanced cervical cancer.
    Huang Y; He Q; Xu K; Zhou J; Yin J; Li F; Feng M; Lang J
    Int J Gynecol Cancer; 2019 Mar; 29(3):459-465. PubMed ID: 30733276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV transcript expression affects cervical cancer response to chemoradiation.
    Ruiz FJ; Inkman M; Rashmi R; Muhammad N; Gabriel N; Miller CA; McLellan MD; Goldstein M; Markovina S; Grigsby PW; Zhang J; Schwarz JK
    JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34255749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer.
    Brodeur MN; Dejean R; Beauchemin MC; Samouëlian V; Cormier B; Bacha OM; Warkus T; Barkati M
    Gynecol Oncol; 2021 Aug; 162(2):277-283. PubMed ID: 34059350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
    Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
    Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer.
    Park S; Kim J; Eom K; Oh S; Kim S; Kim G; Ahn S; Park KH; Chung D; Lee H
    BMC Cancer; 2019 May; 19(1):419. PubMed ID: 31060525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
    Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
    Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent prognostic role of human papillomavirus genotype in cervical cancer.
    Hang D; Jia M; Ma H; Zhou J; Feng X; Lyu Z; Yin J; Cui H; Yin Y; Jin G; Hu Z; Shen H; Zhang K; Li N; Dai M
    BMC Infect Dis; 2017 Jun; 17(1):391. PubMed ID: 28583086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIGO Classification 2018: Validation Study in Patients With Locally Advanced Cervix Cancer Treated With Chemoradiation.
    Raut A; Chopra S; Mittal P; Patil G; Mahantshetty U; Gurram L; Swamidas J; Ghosh J; Gulia S; Popat P; Deodhar K; Maheshwari A; Gupta S
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1248-1256. PubMed ID: 32681859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors of human papillomavirus genotypes of invasive cervical carcinoma: an analytical cross-sectional study in lower north-east Thailand.
    Wongsena M; Suebsamran P; Panomket P; Tirat S; Wongsena P; Wanram S
    J Med Assoc Thai; 2014 Apr; 97 Suppl 4():S12-9. PubMed ID: 24851559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
    Binbin T; Lingying W; Manni H; Jusheng A; Ning L
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To study the role of pre-treatment microRNA (micro ribonucleic acid) expression as a predictor of response to chemoradiation in locally advanced carcinoma cervix.
    Barik S; Mitra S; Suryavanshi M; Dewan A; Kaur I; Kumar D; Mishra M; Vishwakarma G
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1348. PubMed ID: 33660436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
    McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
    Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor prognosis associated with human papillomavirus α7 genotypes in cervical carcinoma cannot be explained by intrinsic radiosensitivity.
    Hall JS; Iype R; Armenoult LS; Taylor J; Miller CJ; Davidson S; de Sanjose S; Bosch X; Stern PL; West CM
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e223-9. PubMed ID: 23332225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus genotype and prognosis of cervical cancer: Favorable survival of patients with HPV16-positive tumors.
    Onuki M; Matsumoto K; Tenjimbayashi Y; Tasaka N; Akiyama A; Sakurai M; Minaguchi T; Oki A; Satoh T; Yoshikawa H
    Papillomavirus Res; 2018 Dec; 6():41-45. PubMed ID: 30347290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Shrinkage During Chemoradiation in Locally Advanced Cervical Cancer Patients: Prognostic Significance, and Impact for Image-Guided Adaptive Brachytherapy.
    Schernberg A; Bockel S; Annede P; Fumagalli I; Escande A; Mignot F; Kissel M; Morice P; Bentivegna E; Gouy S; Deutsch E; Haie-Meder C; Chargari C
    Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):362-372. PubMed ID: 29920324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer.
    Kim JY; Byun SJ; Kim YS; Nam JH
    Gynecol Oncol; 2017 Jan; 144(1):34-39. PubMed ID: 27789082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation between mutation of p53 gene 2-4 exons from peripheral blood and HPV16 positive cervical cancer susceptibility and clinical significance].
    Yin CM; Yao YF; Yan ZL; Yang HY
    Zhonghua Fu Chan Ke Za Zhi; 2017 May; 52(5):320-326. PubMed ID: 28545270
    [No Abstract]   [Full Text] [Related]  

  • 20. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
    Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.